# Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Canonical URL: https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-present-interim-mrt-8102-phase-1-study-results-ae13a1e6
Ticker: GLUE
Company: Monte Rosa Therapeutics
Source: Monte Rosa Therapeutics
Published: 2026-01-06 21:05 EST
## Summary

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced t...

## Article Body
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, including interim data from the ongoing Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com . Registration for the conference call is available at the following link . An archived version of the webcast will be made available for 30 days following the presentation.

About Monte Rosa Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com .

Investors Andrew Funderburk ir@monterosatx.com

Media Cory Tromblee, Scient PR media@monterosatx.com
## Recent Company News
- 2026-07-02 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc49cd8f) — Source: Monte Rosa Therapeutics
- 2026-06-02 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-e01d3eb4) — Source: Monte Rosa Therapeutics
- 2026-05-20 11:00 EST — [Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-620dbf2c) — Source: Monte Rosa Therapeutics
- 2026-05-07 11:00 EST — [Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-first-quarter-2026-financial-results-and-busin-705bfd4d) — Source: Monte Rosa Therapeutics
- 2026-05-05 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-68df4851) — Source: Monte Rosa Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)